Investigational drug · Phase 3
IIV-HD
Also called: standalone
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for COVID-19 Immunization, Influenza Immunization, Immunization.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
9
Any phase or sponsor naming "IIV-HD"
First trial start
2024
Nov 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IIV-HD", any sponsor or status.
Conditions studied
As listed on its trial records.
- COVID-19 Immunization
- Influenza Immunization
- Immunization
- Healthy Volunteers
Approved drugs for the same conditions: COVID-19 · Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "IIV-HD" as an intervention, largest first.
Kaiser PermanenteAcademic, hospital or other
NCT06029933 · 1,500,000 participants (planned) · Start Aug 17, 2023 · Primary completion May 2027
Drug: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4); High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4) · For: Influenza; Community-acquired Pneumonia; Cardiovascular Events
Sites: Oakland, California
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07890454 · 6,000 participants (planned) · Start Oct 28, 2026 · Primary completion Dec 28, 2027
Drug: IIV-HD (standalone); NVXC19 (EU licensed, standalone) and 2 more · For: Immunization; Healthy Volunteers; COVID-19 Immunization and 1 more
Sites: Wroclaw, Poland; Gdynia, Poland
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of AgePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06641180 · 1,180 participants · Start Nov 4, 2024 · Primary completion Jan 28, 2025
Drug: High-Dose trivalent influenza vaccine (Split virion, Inactivated); Standard-dose trivalent influenza vaccine (Split virion, Inactivated) · For: Influenza
Sites: Los Alamitos, California; Fort Myers, Florida; Hollywood, Florida · 20 sites in all
SanofiSanofi (SNY)
NCT06695117 · 980 participants · Start Nov 19, 2024 · Primary completion Apr 16, 2026
Drug: IIV-HD; rC19 (dose 1) and 4 more · For: COVID-19 Immunization; Influenza Immunization
Sites: Birmingham, Alabama; Huntsville, Alabama; Tucson, Arizona · 12 sites in all
- High vs. Standard Dose Influenza Vaccine in Adult SOT RecipientsPivotal-lookingActive, not recruiting
Vanderbilt University Medical CenterAcademic, hospital or other
NCT04613206 · 396 participants (planned) · Start Jan 11, 2021 · Primary completion Jul 1, 2027
Drug: High Dose Quadrivalent Inactivated Influenza Vaccine; Standard Dose Quadrivalent Inactivated Influenza Vaccine · For: Immunization; Infection; Transplantation Infection; Influenza and 1 more
Sites: Nashville, Tennessee
- Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older AdultsPivotal-lookingCompleted
FluGen IncIndustry
NCT05163847 · 303 participants · Start Jun 14, 2022 · Primary completion Nov 3, 2022
Drug: Cam2020 M2SR H3N2 influenza vaccine; Fluzone HD IIV · For: Influenza Vaccine
Sites: Port Orange, Florida; Meridian, Idaho; Lenexa, Kansas · 6 sites in all
- Immunogenicity of Standard-Dose Versus High-Dose Influenza Vaccines in Older Adults in SingaporePivotal-lookingNot yet recruiting
Tan Tock Seng HospitalAcademic, hospital or other
NCT07883421 · 150 participants (planned) · Start Nov 2026 · Primary completion Mar 2027
Drug: High-dose influenza vaccine; Standard-dose influenza vaccine · For: Influenza
Sites: Singapore, Singapore
- The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)Pivotal-lookingStatus unknown
Nova Immunotherapeutics LimitedIndustry
NCT02500680 · 102 participants · Start Jul 2015 · Primary completion Dec 2020
Drug: MER4101; Inactivated Influenza Vaccine · For: Influenza, Human
Sites: St Louis, Missouri
Vanderbilt University Medical CenterAcademic, hospital or other
NCT07192458 · 60 participants (planned) · Start Sep 17, 2025 · Primary completion Dec 2028
Drug: Fluzone High Dose Inactivated Influenza Vaccine; Fluzone Standard Dose Inactivated Influenza Vaccine · For: Immunization; Infection|Transplantation Infection|Influenza; Influenza
Sites: Nashville, Tennessee
Newest research
PubMed records naming it or its code names, newest first.
- Neural Stability Enhancement Through Dynamic Lipschitz Constraints in Generative Adversarial Networks.
Zhang J, Weng Y, Zhao X, et al. · Int J Neural Syst 2027
- Crystal Violet Staining for Colitis-associated Neoplasia-guided Delineation of Ulcerative Colitis-associated Neoplasia for Endoscopic Submucosal Dissection: A Four-case Report.
Tomioka A, Chiya N, Hokari R, et al. · DEN Open 2027
- Evaluation of Large Language Models in the Clinical Management of Patients With Upper Gastrointestinal Bleeding: Insights From Real-World Patient Data.
Rajabnia M, Davoodi F, Hajisafarali M, et al. · DEN Open 2027
- Ion mobility mass spectrometry for suspect screening of environmental toxicants: Collision cross sections, structural annotation, and fit-for-purpose evidence evaluation.
Jin M, Zhou Q, Wu W · Talanta 2027
- Infection-Resistant Alloys for Implants.
Bandyopadhyay A, Upadhayay L, Goodman SB, et al. · Prog Mater Sci 2027
- Enhancing near-infrared spectroscopy by density scaling for improved prediction of mechanical properties of hybrid larch wood.
Zhou F, Zhou Y, Gao X, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
Also in development for COVID-19 Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.